🇪🇺 ABP 938 in European Union

EMA authorised ABP 938 on 14 April 2026

Marketing authorisation

EMA — authorised 14 April 2026

  • Application: EMEA/H/C/006339
  • Marketing authorisation holder: Amgen Technology (Ireland) UC
  • Local brand name: Pavblu
  • Indication: Pavblu is indicated for adults for the treatment of neovascular (wet) age-related macular degeneration (AMD) (see section 5.1), visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1), visual impairment due to diabetic macular oedema (DME) (see section 5.1), visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1).
  • Pathway: biosimilar
  • Status: approved

On 14 April 2026, the European Medicines Agency (EMA) granted marketing authorisation for Pavblu (ABP 938), a biosimilar, for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion, diabetic macular oedema, and visual impairment due to myopic choroidal neovascularisation. This authorisation was granted to Amgen Technology (Ireland) UC, the marketing authorisation holder. Pavblu is indicated for the treatment of these eye conditions in adults.

Read official source →

ABP 938 in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Bone metabolism / Osteoporosis approved in European Union

Frequently asked questions

Is ABP 938 approved in European Union?

Yes. EMA authorised it on 14 April 2026.

Who is the marketing authorisation holder for ABP 938 in European Union?

Amgen Technology (Ireland) UC holds the EU marketing authorisation.